Schizophrenia Clinical Trial
Official title:
A Randomised, Double-blind, Placebo-controlled, Single and Repeated Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AUT00206 in Healthy Volunteers.
The study medicine is a potential future treatment for schizophrenia, an illness that
affects the way that people think, feel or behave. It is not clear what causes
schizophrenia, but it's been linked to chemical imbalance in the brain. It is hoped that the
study medicine will activate specific sites in the brain to help correct that imbalance.
Current treatments for schizophrenia don't work very well and can cause unpleasant side
effects. It is hoped that the study medicine will work better, and have fewer side effects
than existing medicines.
In this 2 part study (Parts A and B), the primary aim is to assess how safe the study
medicine is in healthy men, aged 18-45 years, and how much of it gets into the blood. Its
effects on the brain will also be tested.
In Part A, up to 24 participants will receive up to 5 single doses of the study medicine
(AUT00206 or placebo) by mouth, either after fasting or after a high fat breakfast. The
study medicine has never been given to humans before, so the initial doses will be small and
the dose level will be increased as the study progresses. Participants may take up to 14
weeks to finish the study. They'll make up to 22 outpatient visits, and stay on the ward up
to 5 times, for 3 nights in a row each time.
In Part B, 24 participants will receive daily doses of the study medicine (AUT00206 or
placebo) for up to 28 days. Participants will take up to 10 weeks to finish the study.
They'll make 6 outpatient visits, and stay on the ward for up to 30 nights, depending on how
long we expect it to take until blood levels of the study medicine level off.
A pharmaceutical company, Autifony Therapeutics Limited, is funding the study. The study
will take place at 1 centre in London.
n/a
Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
| Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
| Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
| Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
| Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
| Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
| Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
| Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
| Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
| Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
| Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
| Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
| Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
| Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
| Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
| Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
| Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |